Computational Drug Design against Ebola Virus Targeting Viral Matrix Protein VP30

Arthi Venkatesan (1) , Lavanya Ravichandran (2) , J Febin Prabhu Dass (3)
(1) Vellore Institute of Technology , India
(2) Vellore Institute of Technology , India
(3) Vellore Institute of Technology , India


Ebola viral disease (EVD) is a deadly infectious hemorrhagic viral fever caused by the Ebola virus with a high mortality rate. Until date, there is no effective drug or vaccination available to combat this condition. This study focuses on designing an effective antiviral drug for Ebola viral disease targeting viral protein 30 (VP30) of Ebola virus, highly required for transcription initiation. The lead molecules were screened for Lipinski rule of five, ADMET study following which molecular docking and bioactivity prediction was carried out. The compounds with the least binding energy were analyzed using interaction software. The results revealed that 6-Hydroxyluteolin and (-)-Arctigenin represent active lead compounds that inhibit the activity of VP30 protein and exhibits efficient pharmacokinetics. Both these compounds are plant-derived flavonoids and possess no known adverse effects on human health. In addition, they bind strongly to the predicted binding site centered on Lys180, suggesting that these two lead molecules can be imperative in designing a potential drug for EVD.

Full text article

Generated from XML file


Afendi, F.M., Okada, T., Yamazaki, M., Hirai-Morita, A., Nakamura, Y., Nakamura, K., Ikeda, S., Takahashi, H., Altaf-Ul-Amin, M., Darusman, L.K., Saito, K., Kanaya, S. 2012. KNApSAcK family databases: integrated metabolite-plant species databases for multifaceted plant research. Plant and Cell Physiology. 53(2):e1.
Aminpour, M., Montemagno, C., Tuszynski, J.A. 2019. An Overview of Molecular Modeling for Drug Discovery with Specific Illustrative Examples of Applications. Molecules. 24(9):1693.
Ascenzi, P., Bocedi, A., Heptonstall, J., Capobianchi, M.R., Di Caro, A., Mastrangelo, E., Bolognesi, M., Ippolito, G. 2008. Ebolavirus and Marburgvirus: insight the Filoviridae family. Molecular Aspects of Medicine. 29(3):151-185.
Baikerikar, S. 2017. Curcumin and Natural Derivatives Inhibit Ebola Viral Proteins: An In Silico Approach. Pharmacognosy Research. 9(Suppl 1):S15-S22.
Baize, S., Pannetier, D., Oestereich, L., Rieger, T., Koivogui, L., Magassouba, N., Soropogui, B., Sow, M.S., Keita, S., de Clerck, H., Tiffany, A., Dominguez, G., Loua, M., Traore, A., Kolie, M., Malano, E.R., Heleze, E., Bocquin, A., Mely, S., Raoul, H. Caro, V., Cadar, D., Gabriel, M., Pahlmann, M., Tappe, D., Schmidt-Chanasit, J., Impouma, B., Diallo, A.K., Formenty, P., Herp, M.V., Gunther, S. 2014. Emergence of Zaire Ebola Virus Disease in Guinea. New England Journal of Medicine. 371(15):1418-1425.
Basler, C.F. 2015. Innate Immune Evasion by Filoviruses. Virology. 479-480:122-130.
Berman, H.M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T.N., Weissig, H., Shindyalov, I.N., Bourne, P.E. 2000. The Protein Data Bank. Nucleic Acids Research. 28(1):235-242.
Biedenkopf, N., Hartlieb, B., Hoenen, T., Becker, S. 2013. Phosphorylation of Ebola Virus VP30 Influences the Composition of the Viral Nucleocapsid Complex: Impact on Viral Transcription and Replication. Journal of Biological Chemistry. 288(16):11165-11174.
Binkowski, T.A., Naghibzadeh, S., Liang, J. 2003. CASTp: Computed Atlas of Surface Topography of proteins. Nucleic Acids Research. 31(13):3352-3355.
Broadhurst, M.J., Brooks, T.J.G., Pollock, N.R. 2016. Diagnosis of Ebola Virus Disease: Past, Present, and Future. Clinical Microbiology Reviews. 29(4):773-793.
Cantoni, D., Rossman, J.S. 2018. Ebolaviruses: New roles for old proteins. PLoS Neglected Tropical Diseases. 12(5):e0006349.
Chiappelli, F., Bakhordarian, A., Thames, A.D., Du, A.M., Jan, A.L., Nahcivan, M., Nguyen, M.T., Sama, N., Manfrini, E., Piva, F., Rocha, R.M., Maida, C.A. 2015. Ebola: translational science considerations. Journal of Translational Medicine. 13:11.
De Clercq, E. 2015. Ebola virus (EBOV) infection: Therapeutic strategies. Biochemical Pharmacology. 93(1):1-10.
de La Vega, M.A., Wong, G., Kobinger, G.P., Qiu, X. 2015. The multiple roles of sGP in Ebola pathogenesis. Viral Immunology. 28(1):3-9.
de Ruyck, J., Brysbaert, G., Blossey, R., Lensink, M.F. 2016. Molecular docking as a popular tool in drug design, an in silico travel. Advances and Applications in Bioinformatics and Chemistry. 9:1-11.
Dhama, K., Karthik, K., Khandia, R., Chakraborty, S., Munjal, A., Latheef, S.K., Kumar, D., Ramakrishnan, M.A., Malik, Y.S., Singh, R., Malik, S.V.S., Singh, R.K., Chaicumpa, W. 2018. Advances in Designing and Developing Vaccines, Drugs, and Therapies to Counter Ebola Virus. Frontiers in Immunology. 9:1803.
Easton, V., McPhillie, M., Garcia-Dorival, I., Barr, J.N., Edwards, T.A., Foster, R., Fishwick, C., Harris, M. 2018. Identification of a small molecule inhibitor of Ebola virus genome replication and transcription using in silico screening. Antiviral Research. 156:46-54.
Feldmann, H., Geisbert, T.W. 2011. Ebola haemorrhagic fever. Lancet. 377(9768):849-862.
Forli, S., Huey, R., Pique, M.E., Sanner, M., Goodsell, D.S., Olson, A.J. 2016. Computational protein-ligand docking and virtual drug screening with the AutoDock suite. Nature Protocols. 11(5):905-919.
Garcia-Godoy, M.J., Lopez-Camacho, E., Garcia-Nieto, J., Nebro, A.J., Aldana-Montes, J.F. 2015. Solving Molecular Docking Problems with Multi-Objective Metaheuristics. Molecules. 20(6):10154-10183.
Geisbert, T.W., Jahrling, P.B. 1995. Differentiation of filoviruses by electron microscopy. Virus Research. 39(2-3):129-150.
Gore, S., Garcia, E.S., Hendrickx, P.M.S., Gutmanas, A., Westbrook, J.D., Yang, H., Feng, Z., Baskaran, K., Berrisford, J.M., Hudson, B.P., Ikegawa, Y., Kobayashi, N., Lawson, C.L., Mading, S., Mak, L., Mukhopadhyay, A., Oldfield, T.J., Patwardhan, A., Peisach, E., Sahni, G., Sekharan, M.R., Sen, S., Shao, C., Smart, O.S., Ulrich, E.L., Yamashita, R., Quesada, M., Young, J.Y., Nakamura, H., Markley, J.L., Berman, H.M., Burley, S.K., Velankar, S., Kleywegt, G.J. 2017. Validation of Structures in the Protein Data Bank. Structure. 25(12):1916-1927.
Guex, N., Peitsch, M.C. 1997. SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis. 18(15):2714-2723.
Hartlieb, B., Muziol, T., Weissenhorn, W., Becker, S. 2007. Crystal structure of the C-terminal domain of Ebola virus VP30 reveals a role in transcription and nucleocapsid association. Proceedings of the National Academy of Sciences of the United States of America. 104(2):624-629.
Hoenen, T., Volchkov, V., Kolesnikova, L., Mittler, E., Timmins, J., Ottmann, M., Reynard, O., Becker, S., Weissenhorn, W. 2005. VP40 octamers are essential for Ebola virus replication. Journal of Virology. 79(3):1898-1905.
Huggins, J., Zhang Z.X., Bray, M. 1999. Antiviral drug therapy of filovirus infections: S-adenosylhomocysteine hydrolase inhibitors inhibit Ebola virus in vitro and in a lethal mouse model. The Journal of Infectious Diseases. 179(Suppl 1):S240-S247.
Joshi, A., Kumar, R., Sharma, A. 2018. Molecular Docking Studies, Bioactivity Score Prediction, Drug Likeness Analysis of GSK-3 Β Inhibitors: A Target Protein Involved in Alzheimer’s Disease. Biosciences Biotechnology Research Asia. 15(2):455-467.
Khan, T., Dixit, S., Ahmad, R., Raza, S., Azad, I., Joshi, S., Khan, A.R. 2017. Molecular docking, PASS analysis, bioactivity score prediction, synthesis, characterization and biological activity evaluation of a functionalized 2-butanone thiosemicarbazone ligand and its complexes. Journal of Chemical Biology. 10(3):91-104.
Kim, S., Thiessen, P.A., Bolton, E.E., Chen, J., Fu, G., Gindulyte, A., Han, L., He, J., He, S., Shoemaker, B.A., Wang, J., Yu, B., Zhang, J., Bryant, S.H. 2016. PubChem Substance and Compound databases. Nucleic Acids Research. 44(D1):D1202-1213.
Kouznetsova, J., Sun, W., Martinez-Romero, C., Tawa, G., Shinn, P., Chen, C.Z., Schimmer, A., Sanderson, P., McKew, J.C., Zheng, W., Garcia-Sastre, A. 2014. Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs. Emerging Microbes & Infections. 3(12):e84.
Laskowski, R.A., Swindells, M.B. 2011. LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. Journal of Chemical Information and Modeling. 51(10):2778-2786.
Lee, J.E., Saphire, E.O. 2009. Ebolavirus glycoprotein structure and mechanism of entry. Future Virology. 4(6):621-635.
Lipinski, C.A. 2004. Lead- and drug-like compounds: the rule-of-five revolution. Drug Discovery Today: Technologies. 1(4):337-341.
Martinez, M.J., Biedenkopf, N., Volchkova, V., Hartlieb, B., Alazard-Dany, N., Reynard, O., Becker, S., Volchkov, V. 2008. Role of Ebola Virus VP30 in Transcription Reinitiation. Journal of Virology. 82(24):12569-12573.
Mühlberger, E. 2007. Filovirus replication and transcription. Future Virology. 2(2):205-215.
Nasution, M.A.F., Toepak, E.P., Alkaff, A.H., Tambunan, U.S.F. 2018. Flexible docking-based molecular dynamics simulation of natural product compounds and Ebola virus Nucleocapsid (EBOV NP): a computational approach to discover new drug for combating Ebola. BMC Bioinformatics. 19(Suppl 14):419.
Passi, D., Sharma, S., Dutta, S.R., Dudeja, P., Sharma, V. 2015. Ebola Virus Disease (The Killer Virus): Another Threat to Humans and Bioterrorism: Brief Review and Recent Updates. Journal of Clinical and Diagnostic Research. 9(6):LE01-LE08.
Picazo, E., Jahrling, P.B. 2015. Small molecule inhibitors of ebola virus infection. Drug Discovery Today. 20(2):277-286.
Pires, D.E., Blundell, T.L., Ascher, D.B. 2015. pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures. Journal of Medicinal Chemistry. 58(9):4066-4072.
Raj, U., Varadwaj, P.K. 2016. Flavonoids as Multi-Target Inhibitors for Proteins Associated with Ebola Virus: In Silico Discovery Using Virtual Screening and Molecular Docking Studies. Interdisciplinary Sciences: Computational Life Sciences. 8(2):132-141.
Roca, A., Afolabi, M.O., Saidu, Y., Kampmann, B. 2015. Ebola: A holistic approach is required to achieve effective management and control. Journal of Allergy and Clinical Immunology. 135(4):856-867.
Sadowski, J., Gasteiger, J., Klebe, G. 1994. Comparison of Automatic Three-Dimensional Model Builders Using 639 X-ray Structures. Journal of Chemical Information and Computer Sciences. 34(4):1000-1008.
Salata, C., Calistri, A., Alvisi, G., Celestino, M., Parolin, C., Palu, G. 2019. Ebola Virus Entry: From Molecular Characterization to Drug Discovery. Viruses. 11(3):274.
Saleh, N.A., Elshemey, W.M. 2017. Structure-based drug design of novel peptidomimetic cellulose derivatives as HCV-NS3 protease inhibitors. Life Sciences. 187:58-63.
Schuler, J., Hudson, M.L., Schwartz, D., Samudrala, R. 2017. A Systematic Review of Computational Drug Discovery, Development, and Repurposing for Ebola Virus Disease Treatment. Molecules. 22(10):E1777.
Seeliger, D., de Groot, B.L. 2010. Ligand docking and binding site analysis with PyMOL and Autodock/Vina. Journal of Computer-Aided Molecular Design. 24(5):417-422.
Shen, Z., Lou, K., Wang, W. 2015. New small-molecule drug design strategies for fighting resistant influenza A. Acta Pharmaceutica Sinica B. 5(5):419-430.
Sneha, P., Doss, C.G.P. 2016. Gliptins in managing diabetes - Reviewing computational strategy. Life Sciences. 166:108-120.
Venkatesan, A., Febin, P.D.J. 2017. Deciphering molecular properties and docking studies of hepatitis C and non-hepatitis C antiviral inhibitors - A computational approach. Life Sciences. 174:8-14.
Venkatesan, A., Rambabu, M., Jayanthi, S., Febin, P.D.J. 2018. Pharmacophore feature prediction and molecular docking approach to identify novel anti-HCV protease inhibitors. Journal of Cellular Biochemistry. 119(1):960-966.
Vlietinck, A.J., De Bruyne, T., Apers, S., Pieters, L.A. 1998. Plant-derived leading compounds for chemotherapy of human immunodeficiency virus (HIV) infection. Planta Medica. 64(2):97-109.
Warren, T.K., Wells, J., Panchal, R.G., Stuthman, K.S., Garza, N.L., Van Tongeren, S.A., Dong, L., Retterer, C.J., Eaton, B.P., Pegoraro, G., Honnold, S., Bantia, S., Kotian, P., Chen, X., Taubenheim, B.R., Weich, L.S., Minning, D.M., Babu, Y.S., Sheridan, W.P., Bavari, S. 2014. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature. 508(7496):402-405.
Weik, M., Modrof, J., Klenk, H.D., Becker, S., Mühlberger, E. 2002. Ebola virus VP30-mediated transcription is regulated by RNA secondary structure formation. Journal of Virology. 76(17):8532-8539.
Xie, H., Li, Y., Yu, F., Xie, X., Qiu, K., Fu, J. 2015. An Investigation of Molecular Docking and Molecular Dynamic Simulation on Imidazopyridines as B-Raf Kinase Inhibitors. International Journal of Molecular Sciences. 16(11):27350-27361.
Xu, W., Luthra, P., Wu, C., Batra, J., Leung, D.W., Basler, C.F., Amarasinghe, G.K. 2017. Ebola virus VP30 and nucleoprotein interactions modulate viral RNA synthesis. Nature Communications. 8:15576.
Yannai, S. 2003. Dictionary of Food Compounds with CD-ROM: Additives, Flavors, and Ingredients. Boca Raton: Chapman & Hall/CRC.
Yu, D.S., Weng, T.H., Wu, X.X., Wang, F.X.C., Lu, X.Y., Wu, H.B., Wu, N.P., Li, L.J., Yao, H.P. 2017. The lifecycle of the Ebola virus in host cells. Oncotarget. 8(33):55750-55759.
Zhao, Y. 2016. Towards Structural Based Drug Development for Ebola Virus Disease. Journal of Chemical Biology & Therapeutics. 1(1):e102.


Arthi Venkatesan
Lavanya Ravichandran
J Febin Prabhu Dass (Primary Contact)
Venkatesan A, Ravichandran L, Dass JFP. Computational Drug Design against Ebola Virus Targeting Viral Matrix Protein VP30. Borneo J Pharm [Internet]. 2019Nov.30 [cited 2022Dec.8];2(2):71-8. Available from:

Article Details